PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for June 8, 2006 Subscribe to this News Feed    
 

Daniel A. Szobel Appointed Vice-President of Global Operations for Stem Cell Company - TheraVitae Group

Dr. Valentin Fulga, CEO of TheraVitae, Group, recently announced the appointment of Daniel A. Szobel, as Vice-President of Global Operations. Mr. Szobel takes immediate charge of TheraVitae’s operations worldwide and will be based in Israel.

Kiryat Weizmann, Israel (PRWEB) June 8, 2006 -- Dr. Valentin Fulga, CEO of TheraVitae, Group, recently announced the appointment of Daniel A. Szobel, as Vice-President of Global Operations. Mr. Szobel takes immediate charge of TheraVitae’s operations worldwide and will be based in Israel.

TheraVitae is a multinational company focused on developing and using stem cells from the patient's own blood to treat a variety of disorders.

Confirming the appointment, on behalf of TheraVitae’s board of directors, Dr. Valentin Fulga, CEO of TheraVitae Group, welcomed Mr. Szobel, “We are delighted that Daniel has chosen to further his already distinguished career with us at Theravitae. He brings with him proven leadership experience with both biotech and multinational pharmaceutical companies and is ideally suited to guiding TheraVitae towards accomplishing our future goals.” said Dr. Fulga.

Szobel, 38, joins TheraVitae from his previous position as Finance and Operations Manager at Schering-Plough, Israel; a position in which he was responsible for all of the logistical and operational aspects of company's activities in Israel. Previously Mr. Szobel gained valuable experience as V.P. of Finance and Administration at leading biotech firm Proneuron Biotechnologies Inc. Szobel graduated with a BA in Accounting and Economics from Tel Aviv University and is a Certified Public Accountant (CPA).

Szobel said that he was looking forward to joining the TheraVitae team and was confident of playing a significant role in leading the company forward saying, “I am excited to join Theravitae's intrepid and experienced management team on the journey to becoming a world leader in the field of Cell Therapy.”

About TheraVitae

TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, Toronto, Canada, Taipei, Taiwan and Hong Kong.

http://www.theravitae.com

Additional Information on Stem Cell Therapy:

VesCell™ Website: http://www.vescell.com

Stem Cell Therapy Blog: http://stem-cell-therapy.blogspot.com

TheraVitae Thailand
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
Phone: 02-664-4290/3
Fax: 02-664-42-89

TheraVitae Israel
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel
Phone: +972-8-9409170
Fax: +972-8-9409167

# # #

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SGFsZi1GYWx1LUhvcnItRW1wdC1JbnNlLVplcm8=

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Jay D. Lenner Jr.
THERAVITAE
1-866-690-2008
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.